Treatment of fibrosis in nonalcoholic fatty liver disease.
Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America. The mechanism of liver injury in NASH involves insulin resistance and oxidative stress as well as cytokine release. Therapeutic interventions aimed at enhancing insulin sensitivity or reducing oxidative stress have been studied. The role of peptide hormones secreted by adipose tissue--adipocytokines--in the potential pathogenesis of NASH is an area of intense research. As the function of adipokines in modulating hepatic inflammation and fibrosis is elucidated, the potential for novel treatment strategies in patients with NASH is likely to be realized.
Hoteit
Maarouf A
MA
Division of Digestive Diseases, Emory University School of Medicine, Whitehead Biomedical Research Building, 615 Michael Street, Room 248, Atlanta, GA 30322, USA.
Anania
Frank A
FA
D052242:Adiponectin / Q000378:metabolism; D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology*; D005234:Fatty Liver / Q000150:complications* / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology*; D008103:Liver Cirrhosis / Q000209:etiology* / Q000628:therapy*; D024821:Metabolic Syndrome / Q000150:complications / Q000378:metabolism; D008687:Metformin / Q000627:therapeutic use; D018384:Oxidative Stress; D012307:Risk Factors; D045162:Thiazolidinediones / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D015431:Weight Loss
C499918:ADIPOQ protein, human; D052242:Adiponectin; D000975:Antioxidants; D016207:Cytokines; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D008687:Metformin; D000637:Transaminases